Transaction in Own Shares

Summary by AI BETAClose X

Hikma Pharmaceuticals Plc has purchased 6,932,584 ordinary shares for £90.9 million as part of its $250 million share repurchase program announced on February 26, 2026. These repurchased shares are intended for cancellation. Following these transactions and the cancellation of repurchased shares, the company will have 214,953,869 ordinary shares in issue, resulting in a total of 214,953,869 voting rights.

Disclaimer*

UK 100

Latest directors dealings